Candida dermatitis: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "* " to "*") |
ClaireLewis (talk | contribs) |
||
| Line 17: | Line 17: | ||
==Management<ref name=management>Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</ref>== | ==Management<ref name=management>Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</ref>== | ||
*Topical nystatin, ketoconazole, or clotrimazole applied twice per day until resolution | *Topical [[nystatin]], [[ketoconazole]], or [[clotrimazole]] applied twice per day until resolution | ||
==Disposition== | ==Disposition== | ||
Revision as of 20:33, 27 September 2019
Background
- Local fungal infection caused by the Candida genus
- Most commonly seen in infants (diaper dermatitis) or intertriginous areas
Clinical Features[1]
- Pruritus and erythematous changes in high risk locations: inguinal folds, axilla, scrotum, intergluteal/inframammary/abdominal folds
Differential Diagnosis
- Tinea cruris
- Atopic Dermatitis
- Contact Dermatitis
Evaluation
- erythematous, macerated, intertriginous plaques with satellite pustules or papules
- KOH prep or culture of skin scrapings
Management[2]
- Topical nystatin, ketoconazole, or clotrimazole applied twice per day until resolution
Disposition
- Outpatient